Substantial doubt about the company's ability to continue as a going concern.
“This raises substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Nov 14, 2022
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Useful current figures from the complete screener profile.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CYPA
this stock
Cyphaira Corp.
|
$24.61M | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$68.47B | +37.5% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$54.01B | +11.7% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$51.92B | +42.6% | +4.3% | 101.1 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CYPA | -1.4% | +43.6% | — | +18.9% | -51.7% |
| SPY | -0.6% | -1.8% | +2.2% | -0.9% | +10.8% |
| vs SPY | -0.8% | +45.4% | — | +19.8% | -62.5% |
